Key Highlights

  • Revenue was USD 3.6 million, against USD 5.4 million in the third quarter of 2025.
  • Gross Margin was 28.5%, against 16.5% in the prior-year quarter.
  • Research and development expense rose to USD 6.2 million on the EscharEx Phase III trial.
  • Cash, equivalents and deposits totaled USD 28.4 million at September 30, 2026.

MediWound (NASDAQ:MDWD) reported third-quarter 2026 Revenue of USD 3.6 million, against an estimate of USD 6.73 million, compared with USD 5.4 million in the third quarter of 2025. Gross Profit was USD 1.0 million, a gross margin of 28.5%, against USD 0.9 million and 16.5% a year earlier.

Net loss was USD 6.0 million, or USD 0.47 per share, compared with a net loss of USD 2.7 million, or USD 0.24 per share, in the prior-year quarter.

Spending, Losses and Nine-Month Results

Research and development expense was USD 6.2 million, against USD 3.5 million, mainly reflecting increased Investment in the EscharEx Phase III VALUE trial. SG&A expense was USD 3.4 million, against USD 4.0 million. The operating loss was USD 8.5 million, against USD 6.5 million, and the adjusted EBITDA loss was USD 7.4 million, against USD 5.4 million.

For the first nine months of 2026, revenue was USD 8.1 million, against USD 15.1 million in the first nine months of 2025, mainly because of lower revenue from development services tied to the U.S. government. Research and Development expense was USD 17.3 million, against USD 9.8 million, and SG&A expense was USD 10.8 million, against USD 10.6 million.

The nine-month operating loss was USD 26.0 million, against USD 17.5 million, and the net loss was USD 16.3 million, or USD 1.27 per share, against USD 16.7 million, or USD 1.53 per share. The change in net loss primarily reflected noncash Warrant Revaluation income of USD 10.3 million in 2026, against USD 1.8 million in 2025. The adjusted EBITDA loss was USD 22.7 million, against USD 13.8 million.

Cash and Government Revenue

As of September 30, 2026, the company had USD 28.4 million in cash, cash equivalents and deposits, compared with USD 53.6 million at year-end 2025. Cash burn during the first nine months of 2026 totaled USD 28.3 million.

During the question session, management was asked about 2026 and 2027 revenue from the U.S. government and BARDA. The company's chief executive said it is a significant part of the USD 24 million to USD 26 million guidance range he referenced.

Trial and Revenue Items Disclosed

On the clinical side, enrollment in the global Phase III VALUE trial in venous leg ulcers continues. The current enrollment target is 216 patients across about 40 sites in the United States, Europe and Israel, and management said the prespecified interim sample size reassessment is scheduled for the end of the first quarter of 2027. During the quarter the Independent Data and Safety Monitoring Board completed its prespecified periodic review, identified no safety concerns and recommended that the trial continue without modifications. The next board meeting is scheduled for early January 2027.

The disclosures tie the increase in research and development spending to the EscharEx Phase III VALUE trial. The decline in nine-month revenue is linked to lower development services revenue related to the U.S. government, and the improvement in gross margin from 16.5% to 28.5% is shown against the lower revenue base.

The reported Balance Sheet figures are cash, cash equivalents and deposits of USD 28.4 million, against USD 53.6 million at year-end 2025, along with nine-month cash burn of USD 28.3 million. Adjusted EBITDA losses are reported for both the quarter and the nine months.